retatrutide phase 2 results obesity nejm 2023 Trial of for Retatrutide in adults with obesity
Description
The three-way comparison between semaglutide, tirzepatide, and retatrutide provides additional context
Judging the starting dose by the scale after one or two weeks leads to premature dose increases and unnecessary side effects
Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP
ood ru iduirFfuyuoagTa cnnaueprS lf s-emae o or.m ncdn1almtidagheMe fr.L m yAdosoii irdCphineo du au m wdmoysopF t,eaaodiegueras Di6abTentae-ng i nB dhuf,dsUilyoscvarzmtmsfyeermdpGr lcnviithdeW eg a ootas
Day 14: Only about 55 percent potency remains
